My Treatment Approach: HER+ Positive Breast Cancer

home / insights / my-treatment-approach-her-positive-breast-cancer

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.

A panel of 3 experts on breast cancer

EP. 1: The Role of HER2 in Breast Cancer and Treatment Goals for HER+ Metastatic Breast Cancer Patients

Tiffany A. Traina, MD;VK Gadi, MD, PhD;Heather McArthur, MD, MPH
May 20th 2024

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

A panel of 3 experts on breast cancer

EP. 2: Evolution of the HER2+ Metastatic Breast Cancer Treatment Landscape

Tiffany A. Traina, MD;VK Gadi, MD, PhD;Heather McArthur, MD, MPH
May 20th 2024

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

A panel of 3 experts on breast cancer

EP. 3: First-Line HER2+ Metastatic Breast Cancer Trials in Focus

Tiffany A. Traina, MD;VK Gadi, MD, PhD;Heather McArthur, MD, MPH
May 28th 2024

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

A panel of 3 experts on breast cancer

EP. 4: Case Study: Treatment Sequencing for a 62 Year Old Woman with HER2+ Metastatic Breast Cancer After Progression on T-DXd

Tiffany A. Traina, MD;VK Gadi, MD, PhD;Heather McArthur, MD, MPH
May 28th 2024

Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.